Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995729 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
A Phase 1 study of Acute Treatment of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 13
- Study locations
NCT06995729: Recruiting Phase 1 study of Acute Treatment of Migraine, sponsored by Pfizer.
NCT06995729 is a Phase 1 study of Acute Treatment of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06995729, a Phase 1 study of Acute Treatment of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs. The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine. Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.
Primary Outcome
Cmax is defined as the maximum observed plasma concentration of zavegepant after administration of a single dose
Conditions Studied
Interventions
- DRUG Zavegepant
Study Locations (13)
North Carolina
- Accellacare - Piedmont - Statesville
- Accellacare of Piedmont HealthCare - Statesville
- Accellacare US Inc. - Winston-Salem
Utah
- Wasatch Clinical Research, LLC - Salt Lake City
- Granger Medical Holladay - Holladay Clinic - Salt Lake City
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Velocity Clinical Research, Washington DC - Washington D.C.
Georgia
- Coastal Heritage Clinical Research - Hinesville
Minnesota
- Clinical Research Institute - Minneapolis
Nebraska
- Children's Hospital & Medical Center - Omaha
New York
- True North Neurology - Port Jefferson Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2027-08-12 |
| Phase | Phase 1 |
What NCT06995729 shows while recruiting
NCT06995729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Acute Treatment of Migraine appearing as the primary indexed condition, and to 1 intervention - of which Zavegepant is the first listed.
NCT06995729 lists 13 locations in 10 states (North Carolina, Utah, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06995729 about?
NCT06995729 is a clinical study titled "A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine". The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participan...
What is the current status of trial NCT06995729?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-05-16. Estimated completion is 2027-08-12.
What conditions does trial NCT06995729 study?
This clinical trial studies the following conditions: Acute Treatment of Migraine.
What interventions are being tested in trial NCT06995729?
The interventions under investigation include: Zavegepant (DRUG).
Who is sponsoring clinical trial NCT06995729?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995729 being conducted?
This trial has 13 study locations across Arkansas, District of Columbia, Georgia, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Treatment of Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06995729's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI